Alleviant System
Phase 3- Indications
- Heart failure with preserved ejection fraction (HFpEF), Heart failure with reduced ejection fraction (HFrEF)
Company intelligence / Profile preview
The Alleviant System has completed first-in-human studies and is currently enrolling in pivotal global trials. It has received FDA Breakthrough Device Designation for both major forms of heart failure. Early results suggest the device can reduce symptoms such as shortness of breath and fatigue by decompressing the left atrium without leaving a permanent implant.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alleviant Medical.